403 related articles for article (PubMed ID: 31655118)
21. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA; Montesion M; Shah N; Sharaf R; Pavlick DC; Sokol ES; Alexander B; Venstrom J; Elvin JA; Ross JS; Williams KJ; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
[TBL] [Abstract][Full Text] [Related]
22. Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape.
Vergara IA; Wilmott JS; Long GV; Scolyer RA
Exp Dermatol; 2022 Jan; 31(1):13-30. PubMed ID: 33455025
[TBL] [Abstract][Full Text] [Related]
23. Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.
Zou Z; Ou Q; Ren Y; Lv Q; Qin L; Zhao L; Su S; Wu X; Bao H; Wang A; Zhu D; Wang X; Shao YW; Liu B
Pigment Cell Melanoma Res; 2020 Jul; 33(4):601-611. PubMed ID: 31944535
[TBL] [Abstract][Full Text] [Related]
24. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
25. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
[TBL] [Abstract][Full Text] [Related]
26. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.
Öztürk Sari Ş; Yilmaz İ; Taşkin OÇ; Narli G; Şen F; Çomoğlu Ş; Firat P; Bİlgİç B; Yilmazbayhan D; Özlük Y; Büyükbabanİ N
Pathology; 2017 Jan; 49(1):55-61. PubMed ID: 27914687
[TBL] [Abstract][Full Text] [Related]
27. Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.
Indini A; Roila F; Grossi F; Massi D; Mandalà M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008570
[TBL] [Abstract][Full Text] [Related]
28. KIT Mutation Incidence and Pattern of Melanoma in Central Europe.
Doma V; Barbai T; Beleaua MA; Kovalszky I; Rásó E; Tímár J
Pathol Oncol Res; 2020 Jan; 26(1):17-22. PubMed ID: 31848942
[TBL] [Abstract][Full Text] [Related]
29. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract][Full Text] [Related]
30. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
31. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
33. Medical bioinformatics in melanoma.
Cheng PF
Curr Opin Oncol; 2018 Mar; 30(2):113-117. PubMed ID: 29227308
[TBL] [Abstract][Full Text] [Related]
34. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.
Sergi MC; Filoni E; Triggiano G; Cazzato G; Internò V; Porta C; Tucci M
Curr Oncol Rep; 2023 Nov; 25(11):1247-1258. PubMed ID: 37773078
[TBL] [Abstract][Full Text] [Related]
35. Evolving Treatment Approaches to Mucosal Melanoma.
Zhang S; Zhang J; Guo J; Si L; Bai X
Curr Oncol Rep; 2022 Oct; 24(10):1261-1271. PubMed ID: 35511393
[TBL] [Abstract][Full Text] [Related]
36. Analysis of TSC1 mutation spectrum in mucosal melanoma.
Ma M; Dai J; Xu T; Yu S; Yu H; Tang H; Yan J; Wu X; Yu J; Chi Z; Si L; Cui C; Sheng X; Kong Y; Guo J
J Cancer Res Clin Oncol; 2018 Feb; 144(2):257-267. PubMed ID: 29185092
[TBL] [Abstract][Full Text] [Related]
37. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
38. KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM; Guhan S; Tsao H
Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
[TBL] [Abstract][Full Text] [Related]
39. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases.
Cinotti E; Chevallier J; Labeille B; Cambazard F; Thomas L; Balme B; Leccia MT; D'Incan M; Vercherin P; Douchet C; Rubegni P; Perrot JL
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1834-1840. PubMed ID: 28543798
[TBL] [Abstract][Full Text] [Related]
40. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J; Tian H; Mao L; Si L
Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
